Hodges M, Salerno D M, Granrud G
Am J Cardiol. 1984 Feb 27;53(5):66B-71B. doi: 10.1016/0002-9149(84)90505-8.
In this multicenter trial, the efficacy and safety of flecainide, a new antiarrhythmic agent, were compared with those of quinidine, a standard antiarrhythmic agent in the United States. A randomized, parallel, placebo-controlled design was used. Flecainide was more effective than quinidine (p less than 0.0001) in reducing ventricular premature complexes, couplets and ventricular tachycardia. Flecainide continued to be effective in reducing ventricular arrhythmias during a 12-month follow-up period. The incidence of side effects was similar for the 2 drugs in both short- and long-term studies. Therefore, flecainide should be an excellent drug to use in treating patients with ventricular arrhythmias classified as either benign or potentially malignant.
在这项多中心试验中，将新型抗心律失常药物氟卡尼的疗效和安全性与美国标准抗心律失常药物奎尼丁进行了比较。采用了随机、平行、安慰剂对照设计。在减少室性早搏、成对室性早搏和室性心动过速方面，氟卡尼比奎尼丁更有效（p<0.0001）。在12个月的随访期内，氟卡尼在减少室性心律失常方面持续有效。在短期和长期研究中，两种药物的副作用发生率相似。因此，氟卡尼应该是治疗分类为良性或潜在恶性室性心律失常患者的一种优秀药物。
